Substituted fused ring cannabinoid receptor compound and application thereof
Patent Information
- Application Number
- CN202380030151.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-21
- Filing Date
- 2023-07-18
- Publication Date
- 2024-11-12
AI Technical Summary
Existing CB2-selective small molecule agonists have shortcomings in bioavailability and therapeutic effect, making it difficult to effectively target diseases such as lupus erythematosus and inflammatory bowel disease, and there are challenges in developing highly selective drugs.
A class of substituted fused-ring cannabinoid receptor compounds was designed. Through specific structural combinations and synthetic routes, compounds with high CB2 receptor binding capacity and selectivity were developed for the treatment of CB2-mediated diseases.
The compound shows good CB2 receptor binding ability and selectivity, reduces nervous system side effects, simplifies the synthesis route and preparation process, and is suitable for treating inflammation and autoimmune diseases.
Smart Images

Figure CN118946565A_ABST
Abstract
Description
Substituted fused-ring cannabinoid receptor compounds and their applications
[0001] This application claims priority to a prior application filed with the State Intellectual Property Office of China on July 21, 2022, with patent application number 202210864884.X, entitled “Substituted fused-ring cannabinoid receptor compounds and their applications.” The entire text of that prior application is incorporated herein by reference. Technical Field
[0002] The present invention belongs to the field of medical technology, and specifically relates to a substituted fused-ring cannabinoid receptor compound, a preparation method and an application thereof. Background Art
[0003] Cannabinoid receptors CB1 and CB2 are key components of the endocannabinoid system and are the primary targets of D9-tetrahydrocannabinol (D9-THC). D9-THC is a psychoactive chemical extracted from cannabis that has a wide range of therapeutic uses (J Clin Invest. 1973 Oct; 52(10): 2411-7). Activated by the lipids of tetrahydrocannabinol (THC), cannabinoid receptor 1 (CB1) is associated with psychoactivity, neuromodulation, and analgesia. Cannabidiol (CBD) has attracted widespread attention due to its pharmacological effects or efficacies, including neuroprotection, analgesia, anti-inflammatory, antioxidant, and anti-epileptic properties. The effects of the endocannabinoid receptor system are mainly highly expressed in the central nervous system, adipocytes, liver cells (hepatocytes), and musculoskeletal tissues. Endocannabinoid agonists include anandamide (AEA) and 2-arachidonoyl glycerol (2-AG). CB1 and CB2 play important roles in a variety of physiological processes, including appetite, pain perception, memory, and immune regulation (Manuel Guzmán, Nat Rev Cancer, 2003 Oct;3(10):745-55.). The two cannabinoid receptors share 44% overall sequence homology and 68% sequence similarity in the transmembrane region (Munro et al., 1993). However, they have different tissue distributions and play different functions in the endocannabinoid system, with CB1 and CB2 being primarily expressed in the central nervous system and immune system, respectively. First, due to their high sequence similarity, the development of therapeutic applications is limited by the selectivity for a single target. CB2 is associated with anti-inflammatory and immunomodulatory effects and has no psychoactive effects. CB2 is expressed in somatic cells and (possibly) the central nervous system (CNS) that control immune function. In addition, studies have shown that secondary metabolites of phytonutrients in plant foods can enhance the activity of CB2 receptors and promote a healthy inflammatory response. In addition, CB2 selective agonists are also a hot topic in the field as high-potential candidate drugs for treating inflammatory and neuropathic pain without CB1 psychoactive properties.
[0004] The initial phase of this project focused on the development of small molecule CB2 agonists. The anti-inflammatory mechanisms of CB2 agonists include: reducing chemoattractant production, reducing the production of PGE and other proinflammatory eicosanoids, reducing endothelial cell activation, inflammatory cell adhesion, rolling, and migration between endothelial cells, reducing proinflammatory cytokine reactive oxygen species, and increasing pro-resolving lipid mediators. The anti-fibrotic mechanisms of CB2 agonists include: reducing TGFB production, reducing fibroblast accumulation and proliferation, reducing collagen production, smooth muscle proliferation and migration; and increasing the recruitment of non-inflammatory macrophages into tissues, phagocytosis of bacteria and cell debris, and macrophage efferocytosis. There remains a pressing need in this field to develop new small molecule agonists with higher CB2 selectivity and improved bioavailability compared to existing small molecule compounds with the same target. In terms of drug development, potential future indications for this target include systemic lupus erythematosus (SLE), diffuse skin thickening, autoimmune diseases, colitis or inflammatory bowel disease, atopic dermatitis, pain, and arthritis.
[0005] Summary of the Invention
[0006] To improve the above technical problems, the present invention provides a compound represented by the following formula I, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof,
[0007] wherein A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 3-20 membered heterocyclyl, 5-20 membered heteroaryl, 5-20 membered heteroaryl and 3-20 membered heterocyclyl;
[0008] Ra is selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, OH, HO-C 1-12 Alkyl, CN, -C(O)C 1-12 Alkyl, -S(O)2C 1-12 Alkyl, -S(=O)C 1-12 Alkyl, -S(C 1-12 Alkyl)2, -C(O)NHC 1-12 Alkyl, -C(O)N(C 1-12 alkyl)2、-C(O)NH2、-N(C 1-12 alkyl)2,=O;
[0009] X1, X2, X3, X4, X5, X6 are the same or different and are independently C, CH, or N, provided that X3, X4, X5 are not N at the same time, or X4, X5, X6 are not N at the same time;
[0010] R1 is selected from halogen, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl;
[0011] A2 is selected from C which is unsubstituted or optionally substituted with one, two or more Rb 6-20 Aryl or 5-20 membered heteroaryl;
[0012] Rb is selected from halogen, halogenated C 1-12 Alkyl, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, CN, OH, NH2, nitro;
[0013] A3 is selected from C which is unsubstituted or optionally substituted with one, two or more Rc 3-20 Cycloalkyl or 3-20 membered heterocyclic group;
[0014] Rc is selected from halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl, NH2, -NHC(O)C 1-12 Alkyl, -NHC 1-12 Alkyl, CN, nitro, -COOC 1-12 Alkyl, HO-C 1-12 Alkyl, OH, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy.
[0015] In one embodiment of the present invention, A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 3-12 membered heterocyclyl, 5-12 membered heteroaryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl;
[0016] Ra is selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, HO-C 1-6 Alkyl, CN, -C(O)C 1-6 Alkyl, -S(O)2C 1-6 Alkyl, -C(O)NHC 1-6 Alkyl, -C(O)NH2, -N(C 1-6 alkyl)2,=O;
[0017] R1 is selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-12 Cycloalkyl;
[0018] A2 is selected from C6- 12 Aryl or 5-12 membered heteroaryl;
[0019] Rb is selected from halogen (especially F, Cl), halogenated C 1-6 Alkyl, CN, C 1-6 Alkoxy, C 1-6 Alkyl, OH;
[0020] A3 is selected from C which is unsubstituted or optionally substituted with one, two or more Rc 3-12 Cycloalkyl or 3-12 membered heterocyclic group; and / or
[0021] Rc is selected from halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, NH2, -NHC(O)C 1-6 Alkyl, -NHC 1-6 Alkyl, CN, -COOC 1-6 Alkyl, HO-C 1-6 Alkyl, OH, C 1-6 Alkoxy.
[0022] In one embodiment of the present invention, Formula I can be selected from the following structures:
[0023] In one embodiment of the present invention, A1 is selected from the following groups which are unsubstituted or optionally substituted with one, two or more Ra: 3-12 membered N-containing heterocyclyl, 5-12 membered N-containing heteroaryl, 5-12 membered N-containing heteroaryl and 3-12 membered N-containing heterocyclyl.
[0024] In one embodiment of the present invention, A1 is selected from the following groups which are unsubstituted or optionally substituted with one, two or more Ra: piperazinyl, piperidinyl, hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl, 1,4-diazepanyl, octahydropyrido[1,2-a]pyrazinyl, 5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazinyl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl or azetidinyl.
[0025] In one embodiment of the present invention, Ra is selected from methyl, ethyl, isopropyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, CN, acetyl, methanesulfonyl, methylaminocarbonyl, dimethylamino, carbamoyl or oxo.
[0026] In one embodiment of the present invention, A1 is selected from 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-(2,2,2-trifluoroethyl)piperazinyl, 4-hydroxyethylpiperazinyl, 3-cyano-4-methylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-methylsulfonylpiperazinyl, 4-methylcarbamoylpiperazinyl, 4-(2,2-difluoroethyl)piperazinyl, 4-Methanesulfonylpiperidinyl, 4-Carbamoylpiperazinyl,
[0027] R1 is selected from methyl, trifluoromethyl, cyclopropyl;
[0028] A2 is selected from phenyl or pyridyl which is unsubstituted or optionally substituted with one, two or more Rb;
[0029] Rb is preferably the following groups: F, Cl, CF3, CN, methoxy, methyl, OH;
[0030] A3 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc:
[0031] The Rc is preferably the following groups: F, methyl, trifluoromethyl, NH2, carbamoyl, acetylamino, methylamino, CN, hydroxymethyl, hydroxyethyl, carbomethoxy, OH.
[0032] In one embodiment of the present invention, the compound represented by formula I has a structure selected from the group consisting of:
[0033] wherein L1 and L2 are independently -CH2-, -CH2-CH2- or -CH2-O-; preferably, L1 is -CH2- and L2 is -CH2-O-, and A1, R1, A2 and Rc have the meanings defined herein.
[0034] In one embodiment of the present invention, the compound represented by formula I has a structure selected from the group consisting of:
[0035] wherein A1, R1, A2 and Rc have the meanings defined herein.
[0036] In one embodiment of the present invention, the compound represented by formula I has a structure selected from the group consisting of:
[0037] wherein A1, R1, A2 and Rc have the meanings defined herein.
[0038] In some preferred embodiments of the present invention, the compound represented by formula I is selected from the following compounds:
[0039] The present invention also provides a method for preparing the compound represented by the above formula I or formulas I-1 to I-10, comprising the following steps:
[0040] Method a.
[0041] Compound Ia reacts with compound HA1 to obtain a compound represented by formula I; or,
[0042] Method b.
[0043] Compound Ib reacts with compound R1-ZnBr to obtain a compound of formula I, provided that R1 is C 3-20 Cycloalkyl; or
[0044] Method c.
[0045] Compound Ic reacts with compound Id to obtain a compound represented by formula I-3;
[0046] wherein A1, A2, A3, R1, X1, X2, X3, X4, X5, and X6 have the same definitions as above.
[0047] The present invention also provides a pharmaceutical composition comprising at least one of the compound represented by Formula I, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof.
[0048] According to an embodiment of the present invention, the pharmaceutical composition is used to prevent or treat a disease or condition mediated by cannabinoid receptors, preferably a disease or condition mediated by cannabinoid receptor 2 (CB2).
[0049] According to an embodiment of the present invention, the cannabinoid receptor-mediated disease or condition includes, but is not limited to, systemic lupus erythematosus (SLE), diffuse skin thickening, autoimmune disease, colitis, inflammatory bowel disease, atopic dermatitis, pain and / or arthritis.
[0050] According to an embodiment of the present invention, the pharmaceutical composition further comprises one, two or more pharmaceutically acceptable excipients.
[0051] According to an embodiment of the present invention, the pharmaceutically acceptable excipient is selected from one, two or more of physiologically or pharmaceutically acceptable carriers, diluents, vehicles and / or excipients.
[0052] According to an embodiment of the present invention, suitable routes of administration of the pharmaceutical composition include but are not limited to oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, intravenous and transdermal administration.
[0053] According to an embodiment of the present invention, the pharmaceutical composition is for oral administration, and the pharmaceutical composition can be in the form of tablets, pills, lozenges, sugar-coated tablets, capsules, oral liquids, and the like.
[0054] According to an embodiment of the present invention, the pharmaceutical composition is used for external topical administration, and the pharmaceutical composition can be an ointment, cream, paste, tincture, plaster, gel, film, paint, aerosol, spray, foam, micro sponge, etc.
[0055] The present invention provides the compound represented by the above formula I, its racemate, stereoisomer, tautomer, isotope-labeled product, solvate, polymorph, pharmaceutically acceptable salt or prodrug, or the use of the pharmaceutical composition in the preparation of a medicament for treating or preventing cannabinoid receptor-mediated diseases or conditions.
[0056] The present invention also provides a method for treating or preventing symptoms or diseases mediated by cannabinoid receptors, comprising administering to an individual in need thereof a preventively or therapeutically effective amount of a compound of formula I of the present invention, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition of the present invention.
[0057] According to an embodiment of the present invention, the cannabinoid receptor-mediated disease or disorder is selected from systemic lupus erythematosus (SLE), diffuse skin thickening, autoimmune disease, colitis, inflammatory bowel disease, atopic dermatitis, pain and / or arthritis.
[0058] In all administration methods of the compound represented by formula I of the present invention, the daily dosage is 0.01 to 200 mg / kg body weight.
[0059] According to embodiments of the present invention, the dosage regimen can be adjusted to provide the optimal desired response. For example, a single oral dose can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It should be noted that dosage values can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering the composition or supervising the administration of the composition. Beneficial effects
[0060] The compounds of the present invention have good binding ability and selectivity for human CB2 receptors and exhibit good agonist activity and high selectivity for CB2 receptors, thereby reducing neurological side effects while treating inflammatory diseases, autoimmune diseases, and other conditions. Furthermore, the compounds of the present invention have the advantages of a short synthetic route, an easy preparation process, and simple product post-processing.
[0061] Definition and Description
[0062] Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs.
[0063] In the present invention, the * in each substituent listed is the connection site.
[0064] "More" means three or more.
[0065] The term "halogen" includes F, Cl, Br or I.
[0066] In the general structure, C(O) represents a carbonyl group, i.e. S(O)2 represents a sulfonyl group, such as -S(O)2R, which represents a structural formula of The dotted lines in the general structure indicate that the chemical bonds at the corresponding positions can be single bonds or double bonds.
[0067] The term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.
[0068] Unless otherwise indicated, numerical ranges recited in this specification and claims are equivalent to recite at least each specific integer value therein. For example, the numerical range "1-20" is equivalent to recite each integer value in the numerical range "1-10," namely, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and each integer value in the numerical range "11-20," namely, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20. Other numerical ranges should be understood and interpreted similarly.
[0069] The term "C 1-12 "Alkyl" is understood to mean a straight-chain or branched saturated monovalent hydrocarbon group having 1 to 12 carbon atoms. For example, "C 1-6The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5, or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, or isomers thereof.
[0070] The term "C 3-20 "Cycloalkyl" should be understood to mean a saturated monovalent monocyclic, bicyclic hydrocarbon ring or polycyclic hydrocarbon ring (also called condensed hydrocarbon ring) having 3-20 carbon atoms. Bicyclic or polycyclic cycloalkyl groups include paracyclic cycloalkyl, bridged cycloalkyl and spirocyclic cycloalkyl; the paracyclic refers to a condensed ring structure formed by two or more cyclic structures sharing two adjacent ring atoms (i.e., sharing a bond). The bridged ring refers to a condensed ring structure formed by two or more cyclic structures sharing two non-adjacent ring atoms. The spirocyclic refers to a condensed ring structure formed by two or more cyclic structures sharing one ring atom. For example, the C 3-20 The cycloalkyl group may be C 3-8 Monocyclic cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or C 7-12 Cycloalkyl, such as decahydronaphthalene ring; can also be C 7-12 Bridged ring cycloalkyl, such as norbornane, adamantane, bicyclo[2,2,2]octane.
[0071] The term "3-20 membered heterocyclyl" means a saturated or unsaturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1 to 5 heteroatoms independently selected from N, O and S, preferably a "3-10 membered heterocyclyl". The term "3-10 membered heterocyclyl" means a saturated or unsaturated monovalent monocyclic or bicyclic hydrocarbon ring containing 1 to 5, preferably 1 to 3 heteroatoms selected from N, O and S. The heterocyclyl group may be attached to the rest of the molecule through any of the carbon atoms or the nitrogen atom (if present). In particular, the heterocyclic group may include, but is not limited to, a 4-membered ring such as azetidinyl, oxetanyl; a 5-membered ring such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or a 7-membered ring such as diazepanyl, diazepanyl. Optionally, the heterocyclic group may be a fused ring, a bridged ring or a spirocyclic ring. The heterocyclic group may be bicyclic, such as, but not limited to, hexahydropyrrolo[1,2-a]pyrazine-2(1H)-yl. The ring containing the nitrogen atom may be partially unsaturated, i.e. it may contain one, two or more double bonds, such as but not limited to 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl, 5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazinyl, or it may be benzo-fused, such as but not limited to dihydroisoquinolinyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl.
[0072] The term "C 6-20 "Aryl" is understood to mean a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring having 6 to 20 carbon atoms, preferably "C 6-14 Aryl". The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14 or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl) such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 aryl”), such as anthracenyl. When the C 6-20 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the substitution position, and for example, the substitution may be at the ortho, para or meta position.
[0073] The term "5-20 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5 to 20 ring atoms and containing 1 to 5 heteroatoms independently selected from N, O and S, for example "5-14 membered heteroaryl". The term "5-14 membered heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 5 or 6 or 9 or 10 carbon atoms, and containing 1 to 5, preferably 1 to 3 heteroatoms each independently selected from N, O and S and, in addition, in each case may be benzo-fused. In particular, the heteroaryl group is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl and the like and benzo derivatives thereof, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl and the like; or acininyl, indolizinyl, purinyl and the like and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl and the like.
[0074] The above term “C 1-12 The definition of "alkyl" also applies to other C-containing 1-12 Alkyl groups, such as C 1-12 Alkoxy, etc.
[0075] Similarly, C 6-20 Aryl, 5-20 membered heteroaryl, C 3-20 Cycloalkyl has the same definition throughout. DETAILED DESCRIPTION
[0076] The technical solutions of the present invention will be described in further detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are encompassed within the scope of protection that the present invention is intended to protect.
[0077] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0078] Example 1: Preparation of 8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-6-(4-methylpiperazin-1-yl)purine (Compound 1)
[0079] Step 1: Synthesis of compound 6-chloro-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-5-nitropyrimidin-4-amine (2)
[0080] To a solution of 2-methyl-4,6-dichloro-5-nitropyrimidine (604.74 mg, 2.90 mmol, 2.00 equiv) in isopropanol (10 mL) at room temperature were added 3-fluorobicyclo[1.1.1]pentane-1-amine hydrochloride (200.00 mg, 1.45 mmol, 1.00 equiv) and N,N-diisopropylethylamine (375.77 mg, 2.90 mmol, 2.00 equiv). After the addition was complete, the system was stirred at room temperature for 1 hour. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction solution was diluted with water (1 x 40 mL) and extracted with ethyl acetate (2 x 40 mL). The combined organic phases were backwashed with saturated brine (1 x 40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 6-chloro-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-5-nitropyrimidin-4-amine (360.40 mg, 90.93%). LCMS (ES, m / z): 272.95 [M+H] + .
[0081] Step 2: Synthesis of compound 6-chloro-N4-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpyrimidine-4,5-diamine (3)
[0082] To a solution of 6-chloro-N-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-5-nitropyrimidin-4-amine (340.00 mg, 1.25 mmol, 1.00 equiv) in anhydrous methanol (10 mL) at room temperature were added reduced iron powder (278.55 mg, 5.00 mmol, 4.00 equiv) and glacial acetic acid (1 mL, 17.45 mmol). After the addition was complete, the system was stirred at room temperature for 2 hours. After completion of the reaction by liquid chromatography-mass spectrometry, the reaction mixture was basified to pH 8 with saturated aqueous sodium bicarbonate. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The organic phases were combined and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 6-chloro-N4-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpyrimidine-4,5-diamine (286.00 mg, 94.51%). LCMS (ES, m / z): 243.00 [M+H] + .
[0083] Step 3: Synthesis of compound 6-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpurine (4)
[0084] Under nitrogen, o-chlorobenzaldehyde (241.35 μL, 2.14 mmol, 2.00 equiv) and ferric chloride (78.00 mg, 0.32 mmol, 0.30 equiv) were added to a solution of 6-chloro-N4-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpyrimidine-4,5-diamine (260.00 mg, 1.07 mmol, 1.00 equiv) in 1,4-dioxane (10 mL) at room temperature. The reaction mixture was heated to 55°C and stirred overnight. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was filtered, and the filter cake was washed with dichloromethane (3 x 10 mL). The resulting residue was concentrated under reduced pressure to yield crude 6-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-7,8-dihydropurine. The crude product was dissolved in dichloromethane (6 mL), and then 2,3-dichloro-5,6-dicyanobenzoquinone (243.02 mg, 1.07 mmol, 1.00 equiv) was added under ice-cooling. The reaction mixture was warmed to room temperature and stirred for 2 hours. Liquid chromatography-mass spectrometry confirmed the reaction was complete. The reaction mixture was quenched with 1 M sodium hydroxide solution, diluted with water (20 mL), and extracted with dichloromethane (2 x 20 mL). The organic phases were combined, backwashed with saturated brine (1 x 30 mL), dried over anhydrous sulfuric acid, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 6-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpurine (285.00 mg, 73.29%). LCMS (ES, m / z): 362.95 [M+H] + .
[0085] Step 4: Synthesis of compound 8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-6-(4-methylpiperazin-1-yl)purine (Compound 1)
[0086] To a solution of 6-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methylpurine (100.00 mg, 0.28 mmol, 1.00 equiv) in 1,4-dioxane (5 mL) was added N-methylpiperazine (30.54 uL, 0.28 mmol, 1.00 equiv) and N,N-diisopropylethylamine (143.87 uL, 0.84 mmol, 3.00 equiv) at room temperature. The reaction mixture was heated to 100°C and stirred for 1 hour. The reaction was complete after liquid chromatography-mass spectrometry monitoring. The reaction mixture was cooled to room temperature, diluted with water (1 x 20 mL), and extracted with ethyl acetate (2 x 30 mL). The organic phases were combined, backwashed with saturated brine (1 x 40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: XBridge Prep OBD C18 Column, 30 x 150 mm, 5 μm; mobile phase A: water (10 mmol / L ammonium bicarbonate), mobile phase B: acetonitrile (flow rate: 60 mL / min); elution gradient: 45% B to 70% B over 8 min; detection wavelength: UV 254 nm / 220 nm. The compound 8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-2-methyl-6-(4-methylpiperazin-1-yl)purine (25.80 mg, 21.84%) was obtained. 1 H NMR(400MHz,DMSO-d6)δ7.70-7.61(m,3H),7.58-7.43(m,1H),4.16(s,4H)2.46( d,J=3.1Hz,9H),2.40(t,J=5.1Hz,4H),2.20(s,3H).LCMS(ES,m / z):427.10[M+H] + .
[0087] The compounds listed in Table 1 below were prepared using conditions similar to those in Example 1. The structural characterization data of these compounds are listed in Table 1.
[0088] Table 1
[0089] Example 2: Preparation of 8-(2-chlorophenyl)-2-cyclopropyl-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (Compound 61)
[0090] Step 1-4: Synthesis of compound 2-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (8)
[0091] A similar method to Example 1 was used (the starting materials were replaced with 2,4,6-trichloro-5-nitropyrimidine and 3-fluorobicyclo[1.1.1]pentan-1-amine hydrochloride) to obtain the compound 2-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (1.20 g, 89.49%). LCMS (ES, m / z): 447.30 [M+H] + .
[0092] Step 5: Synthesis of compound 8-(2-chlorophenyl)-2-cyclopropyl-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (Compound 61)
[0093] To a solution of 2-chloro-8-(2-chlorophenyl)-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (500.00 mg, 1.12 mmol, 1.00 equiv) in 1,4-dioxane (10 mL) was added 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (53.28 mg, 0.11 mmole) at room temperature under nitrogen. To the reaction mixture was added (2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) methanesulfonate (94.61 mg, 0.11 mmol, 0.10 equiv), followed by the dropwise addition of a 0.5 M solution of cyclopropylzinc bromide in tetrahydrofuran (6.70 mL, 3.36 mmol, 3.00 equiv). The mixture was heated to 100°C and stirred for 1 hour. The reaction was complete as determined by liquid chromatography-mass spectrometry. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with dichloromethane (3 x 10 mL). The filtrate was concentrated under reduced pressure. The mixture was diluted with water (100 mL) and extracted with dichloromethane (3 x 100 mL). The organic phases were combined, backwashed with saturated sodium chloride solution (1 x 100 mL), and dried over anhydrous sodium sulfate. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC using the following conditions: XBridge Prep OBD C18 Column, 30 x 150 mm, 5 μm; Mobile Phase A: Water (10 mmol / L ammonium bicarbonate), Mobile Phase B: Acetonitrile; Flow Rate: 60 mL / min; Elution Gradient: 45% B to 90% B over 8 minutes, 90% B; Detection: UV 254 nm / 220 nm; Retention Time (min): 7.7. The compound 8-(2-chlorophenyl)-2-cyclopropyl-9-{3-fluorobicyclo[1.1.1]pentan-1-yl}-6-(4-methylpiperazin-1-yl)purine (143.00 mg, 28.02%) was obtained. 1 H NMR (400MHz, DMSO-d6) δ7.69-7.64(m,2H),7.64-7.59(m,1H),7.58-7.48(m,1H),4.14(s,4H),2.45(d,J=2.1H z,6H),2.39(t,J=5.1Hz,4H),2.20(s,3H),2.07-1.97(m,1H),1.02-0.89(m,4H).LCMS(ES,m / z):452.95[M+H] + .
[0094] Example 3: Preparation of 1-(1-{bicyclo[1.1.1]pentan-1-yl}-2-(2-chlorophenyl)-6-methylimidazo[4,5-c]pyridin-4-yl)-4-methylpiperazine (Compound 62)
[0095] A similar method to Example 1 was used (the starting materials were replaced with 2,4-dichloro-6-methyl-3-nitropyridine and bicyclo[1.1.1]pentachlorobenzene-1-amine) to obtain the compound 1-(1-{bicyclo[1.1.1]pentan-1-yl}-2-(2-chlorophenyl)-6-methylimidazo[4,5-c]pyridin-4-yl)-4-methylpiperazine (26.50 mg, 22.23%). 1 H NMR (400 MHz, deuterated methanol) δ 7.52-7.47 (m, 2H), 7.46-7.42 (m, 1H), 7.41-7.35 (m, 1H), 6.86 (d, J = 0.8 Hz, 1H), 3.91 (s, 4H), 2.51 (t, J = 4.7 Hz, 4H), 2.37 (t, J = 1.1 Hz, 4H), 2.24 (d, J = 1.3 Hz, 3H), 2.09 (d, J = 1.7 Hz, 6H). LCMS (ES, m / z): 409.05 [M+H] + .
[0096] The compounds listed in Table 2 below were prepared using conditions similar to those in Example 3. The structural characterization data of these compounds are listed in Table 2.
[0097] Table 2
[0098] Example 4: Preparation of 1-(3-{bicyclo[1.1.1]pentan-1-yl}-2-(2-chlorophenyl)-5-methylimidazo[4,5-b]pyridin-7-yl)-4-methylpiperazine (Compound 65)
[0099] Step 1: Synthesis of compound 1-(2-chloro-6-methyl-3-nitropyridin-4-yl)-4-methylpiperazine (14)
[0100] A similar method to that in step 4 of Example 1 was used (the starting material was replaced with 2,4-dichloro-6-methyl-3-nitropyridine) to obtain the compound 1-(2-chloro-6-methyl-3-nitropyridin-4-yl)-4-methylpiperazine (700.00 mg, 53.53%). LCMS (ES, m / z): 271.00 [M+H] + .
[0101] The subsequent three steps were carried out using a method similar to steps 1, 2 and 3 of Example 1 (the starting materials were replaced with 1-(2-chloro-6-methyl-3-nitropyridin-4-yl)-4-methylpiperazine and bicyclo[1.1.1]pentachlorobenzene-1-amine) to obtain compound 1-(3-{bicyclo[1.1.1]pentan-1-yl}-2-(2-chlorophenyl)-5-methylimidazo[4,5-b]pyridin-7-yl)-4-methylpiperazine (10.60 mg, 6.79%). 1 H NMR (400 MHz, deuterated methanol) δ 7.52-7.41 (m, 3H), 7.40-7.35 (m, 1H), 6.43 (s, 1H), 3.64 (s, 4H), 2.56 (t, J = 5.1 Hz, 4H), 2.43 (s, 3H), 2.33 (s, 1H), 2.26 (s, 3H), 2.14 (d, J = 4.1 Hz, 6H). LCMS (ES, m / z): 408.05 [M+H] + .
[0102] Biological test evaluation
[0103] Test Example 1 Human CB2 ligand receptor binding assay
[0104] The affinity of the compounds of the present invention for human CB2 receptors was tested using a radioisotope-labeled ligand receptor binding assay. 95 μL of assay buffer (25 mM Hepes, 10 mM MgCl2, 1 mM CaCl2, 0.5% BSA, pH 7.4) was added to a 96-well deep-well assay plate, followed by the addition of 5 μL of 100X compound to the corresponding wells, followed by shaking at 600 rpm for 5 minutes to mix. 300 μL of a mixture of CHO-CB2 cell membrane and assay buffer (0.2 μL membrane and 299.8 μL assay buffer) was added to each well, followed by shaking at 600 rpm for 5 minutes to mix. 100 μL of 5X concentration of isotope [ 3[H]-CP 55940 was added to each well, centrifuged at 1000 rpm for 1 minute, and then shaken at 600 rpm for 5 minutes to mix. The plates were then incubated at 30°C for 1.5 hours. A UNIFILTER-96GF / C plate, which had been incubated at 4°C for 1 hour with 0.5% PEI solution, was washed twice with 50 mL of wash buffer (50 mM Tris-HCl, 2.5 mM EDTA, 5 mM MgCl2, 0.5 mg / ml BSA, pH 7.4). The reactions in the 96-well deep-well plate were transferred to a UNIFILTER-96GF / C plate and washed four times with 900 μL of wash buffer per well. The washed UNIFILTER-96GF / C plate was dried in a 55°C oven for 10 minutes. 40 μL of ULTIMA GOLD scintillation fluid was added to each well of the dried UNIFILTER-96GF / C plate, and data were collected using a Microbeta2. The entire reaction system is 500 μL. 3 The final concentration of [H]-CP 55940 was 0.5 nM, and the final concentration of DMSO was 1%.
[0105] The dose-effect curves of the compounds were generated using the nonlinear four-parameter equation of XLfit or GraphPad Prism software and the corresponding Ki values were calculated.
[0106] The compounds of the present invention have good binding ability to human CB2 receptors. The binding data of some compounds are shown in Table 3 below.
[0107] Table 3
[0108] Test Example 2 CB1 and CB2 cAMP generation function test
[0109] Flp-In-CHO human CB1 / 2, Flp-In-CHO mouse CB1 / 2, and Flp-In-CHO rat CB1 / 2 cells were cultured in F12K complete medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 600 μg / ml hygromycin at 37°C in a 5% CO2 incubator. On the day of the experiment, cells were digested and resuspended in HBSS-based assay buffer containing 20 mM HEPES, 0.1% BSA, and 500 μM IBMX, then seeded into 384-well cell culture plates. The seeding density for human and mouse CB1 / 2 cells was 8,000 cells per well, while the seeding density for rat CB1 / 2 cells was 2,000 cells per well in a 15 μL seeding volume. The agonist activity of the above compounds at human CB1 and CB2 receptors was then assessed using a cAMP generation assay.
[0110] Human CB2 agonist assay
[0111] Add 2.5 μL of 8X SR144528 working solution to the above cell assay plate. Incubate at 37°C for 10 minutes. Then, add 2.5 μL of a mixture of 8X compound and forskolin and incubate at 37°C for 30 minutes. After the reaction is complete, add 10 μL of Eu-cAMP tracer and 10 μL of Ulight-anti-cAMP detection reagent to the assay plate. Incubate at room temperature for 1 hour, and then collect data using the Envision HTRF function module. The total reaction volume is 20 μL, with a final DMSO concentration of 0.2%, a final forskolin concentration of 2 μM, and a final SR144528 concentration of 80 nM.
[0112] Use the nonlinear four-parameter equation of XLfit or GraphPad Prism software to generate the dose-effect curve of the compound and calculate its corresponding EC 50 .
[0113] The compounds of the present invention exhibit good human CB2 agonist activity. The human CB2 agonist activity of some of the compounds is shown in Table 4 below.
[0114] Table 4
[0115] Human CB1 agonist assay
[0116] Add 2.5 μL of 8X compound working solution to the cell assay plate and incubate at 37°C for 10 minutes. Then, add 2.5 μL of 8X forskolin solution and incubate at 37°C for 30 minutes. After the reaction is complete, add 10 μL of Eu-cAMP tracer and 10 μL of Ulight-anti-cAMP detection reagent to the plate. Incubate at room temperature for 1 hour before collecting data using the Envision HTRF function module. The total reaction volume is 20 μL, with a final DMSO concentration of 0.2% and a final forskolin concentration of 1 μM.
[0117] Use the nonlinear four-parameter equation of XLfit or GraphPad Prism software to generate the dose-effect curve of the compound and calculate its corresponding EC 50 .
[0118] The compounds of the present invention show good selectivity for human CB1 agonism. The human CB1 agonist activities of some of the compounds are shown in Table 5 below.
[0119] Table 5
[0120] As a control, the following compounds were used to obtain the test results shown in Table 6.
[0121] Table 6
[0122] By comparing the human CB2 ligand binding activity and human CB2 agonist activity data of the compound of the present invention and the control compound LY-2828360, it can be seen that the compound of the present invention has better biological activity for CB2 receptors and has good selectivity for CB2 receptors.
[0123] The above describes the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.
Claims
1. A compound of formula I, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt, or prodrug thereof, in, A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 3-20 membered heterocyclyl, 5-20 membered heteroaryl, 5-20 membered heteroaryl and 3-20 membered heterocyclyl; Ra is selected from C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, OH, HO-C 1-12 Alkyl, CN, -C(O)C 1-12 Alkyl, -S(O)2C 1-12 Alkyl, -S(=O)C 1-12 Alkyl, -S(C 1-12 Alkyl)2, -C(O)NHC 1-12 Alkyl, -C(O)N(C 1-12 alkyl)2、-C(O)NH2、-N(C 1-12 alkyl)2,=O; X1, X2, X3, X4, X5, X6 are the same or different and are independently C, CH, or N, provided that X3, X4, X5 are not N at the same time, or X4, X5, X6 are not N at the same time; R1 is selected from halogen, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkyl, halogenated C 1-12 Alkoxy, C 3-20 Cycloalkyl; A2 is selected from C which is unsubstituted or optionally substituted with one, two or more Rb 6-20 Aryl or 5-20 membered heteroaryl; Rb is selected from halogen, halogenated C 1-12 Alkyl, C 1-12 Alkyl, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy, CN, OH, NH2, nitro; A3 is selected from C which is unsubstituted or optionally substituted with one, two or more Rc 3-20 Cycloalkyl or 3-20 membered heterocyclic group; Rc is selected from halogen, C 1-12 Alkyl, halogenated C 1-12 Alkyl, NH2, -NHC(O)C 1-12 Alkyl, -NHC 1-12 Alkyl, CN, nitro, -COOC 1-12 Alkyl, HO-C 1-12 Alkyl, OH, C 1-12 Alkoxy, halogenated C 1-12 Alkoxy.
2. The compound of formula I according to claim 1, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 3-12 membered heterocyclyl, 5-12 membered heteroaryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl; Ra is selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, HO-C 1-6 Alkyl, CN, -C(O)C 1-6 Alkyl, -S(O)2C 1-6 Alkyl, -C(O)NHC 1-6 Alkyl, -C(O)NH2, -N(C 1-6 alkyl)2,=O; R1 is selected from C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 3-12 Cycloalkyl; A2 is selected from C which is unsubstituted or optionally substituted with one, two or more Rb 6-12 Aryl or 5-12 membered heteroaryl; Rb is selected from halogen (especially F, Cl), halogenated C 1-6 Alkyl, CN, C 1-6 Alkoxy, C 1-6 Alkyl, OH; A3 is selected from C which is unsubstituted or optionally substituted with one, two or more Rc 3-12 Cycloalkyl or 3-12 membered heterocyclic group; and / or Rc is selected from halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, NH2, -NHC(O)C 1-6 Alkyl, -NHC 1-6 Alkyl, CN, -COOC 1-6 Alkyl, HO-C 1-6 Alkyl, OH, C 1-6 Alkoxy.
3. The compound of formula I according to claim 1 or 2, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: Formula I is selected from the following structures:
4. The compound of formula I according to any one of claims 1 to 3, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: 3-12 membered N-containing heterocyclic group, 5-12 membered N-containing heteroaryl group, 5-12 membered N-containing heteroaryl group and 3-12 membered N-containing heterocyclic group; Preferably, A1 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Ra: piperazinyl, piperidinyl, hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl, 1,4-diazepanyl, octahydropyrido[1,2-a]pyrazinyl, 5H,6H,8H-[1,2,4]triazolo[4,3-a]pyrazinyl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl or azetidinyl.
5. The compound of formula I according to any one of claims 1 to 4, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: Ra is selected from methyl, ethyl, isopropyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-hydroxyethyl, CN, acetyl, methanesulfonyl, methylaminocarbonyl, dimethylamino, carbamoyl or oxo.
6. The compound of formula I according to any one of claims 1 to 5, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: A1 is selected from 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-(2,2,2-trifluoroethyl)piperazinyl, 4-hydroxyethylpiperazinyl, 3-cyano-4-methylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-methylsulfonylpiperazinyl, 4-methylcarbamoylpiperazinyl, 4-(2,2-difluoroethyl)piperazinyl, 4-Methanesulfonylpiperidinyl, 4-Carbamoylpiperazinyl, 7. The compound of formula I according to any one of claims 1 to 6, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: R1 is selected from methyl, trifluoromethyl, and cyclopropyl.
8. The compound of formula I according to any one of claims 1 to 7, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: A2 is selected from phenyl or pyridyl which is unsubstituted or optionally substituted with one, two or more Rb.
9. The compound of formula I according to any one of claims 1 to 8, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: Rb is the following groups: F, Cl, CF3, CN, methoxy, methyl, OH.
10. The compound of formula I according to any one of claims 1 to 9, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: A3 is selected from the following groups which are unsubstituted or optionally substituted by one, two or more Rc:
11. The compound of formula I according to any one of claims 1 to 10, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: Rc is the following groups: F, methyl, trifluoromethyl, NH2, carbamoyl, acetylamino, methylamino, CN, hydroxymethyl, hydroxyethyl, carbomethoxy, OH.
12. The compound of formula I according to any one of claims 1 to 10, its racemate, stereoisomer, tautomer, isotope-labeled substance, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, wherein: The compound represented by formula I has a structure selected from I-8, I-9 or I-10: Wherein, L1 and L2 are independently -CH2-, -CH2-CH2- or -CH2-O-; preferably, L1 is -CH2- and L2 is -CH2-O-.
13. The compound of formula I according to any one of claims 1 to 10, which has a structure selected from the following:
14. A pharmaceutical composition comprising at least one of the compound of formula I according to any one of claims 1 to 13, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt, or prodrug thereof; Preferably, the pharmaceutical composition further comprises one, two or more pharmaceutically acceptable excipients.
15. The pharmaceutical composition according to claim 14, characterized in that The pharmaceutical composition is used to prevent or treat a disease or condition mediated by cannabinoid receptors, preferably a disease or condition mediated by cannabinoid receptor 2 (CB2); Preferably, the cannabinoid receptor mediated disease or condition is selected from the group consisting of systemic lupus erythematosus (SLE), diffuse skin thickening, autoimmune disease, colitis, inflammatory bowel disease, atopic dermatitis, pain and / or arthritis.
16. Use of a compound of formula I according to any one of claims 1 to 13, its racemate, stereoisomer, tautomer, isotope-labeled form, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition according to claim 14 or 15 in the preparation of a medicament for treating or preventing a disease or condition mediated by a cannabinoid receptor.
Citation Information
Patent Citations
Purine compounds
CN102256977A
Purine compounds
CN102803266A
Bicyclic compounds
CN107849036A
Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation
US20080234259A1
Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
WO1999040091A1
